Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 3/20 | 0.33 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23204650 | 0.83 | CACNA2D1 (0.36) | CACNA2D1CACNA1BCACNB1ACHECHRM5 | |
| SCHEMBL23204652 | 0.83 | CACNA2D1 (0.36) | CACNA2D1CACNA1BCACNB1ACHECHRM5 | |
| SCHEMBL24414411 | 0.80 | ACHE (0.40) | CACNA2D1CACNA1BCACNB1GBA1ACHE | |
| SCHEMBL24717543 | 0.80 | GBA1 (0.43) | CACNA2D1CACNA1BCACNB1GBA1ACHE | |
| SCHEMBL23205744 | 0.79 | ACHE (0.35) | CACNA2D1CACNA1BCACNB1GBA1ACHE | |
| SCHEMBL23205510 | 0.79 | ACHE (0.35) | CACNA2D1CACNA1BCACNB1GBA1ACHE | |
| SCHEMBL3309077 | 0.77 | CHRM5 (0.39) | CACNA2D1CACNA1BCACNB1GBA1ACHE | |
| SCHEMBL24802104 | 0.76 | GBA1 (0.40) | CACNA2D1CACNA1BCACNB1GBA1ACHE | |
| SCHEMBL24717621 | 0.76 | HTR6 (0.36) | — | |
| SCHEMBL24717700 | 0.76 | HTR6 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151557-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20220395576-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220395576-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | BCL6, BCL6B, BCL3 | CACNA2D1 4647/4885CACNA1B 4330/4885CACNB1 3899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.